Funds and ETFs Ocean Biomedical, Inc.

Equities

OCEA

US67644C1045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:20:50 2024-04-18 am EDT 5-day change 1st Jan Change
1.815 USD +1.68% Intraday chart for Ocean Biomedical, Inc. -17.01% +177.27%

ETFs positioned on Ocean Biomedical, Inc.

Name Weight AuM 1st Jan change Investor Rating
0.00% 34 M€ +1.51% -
Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
More about the company
  1. Stock Market
  2. Equities
  3. OCEA Stock
  4. Funds and ETFs Ocean Biomedical, Inc.